Difference between revisions of "Tucatinib (Tukysa)"
Jump to navigation
Jump to search
m (Jwarner moved page Tucatinib (ARRY-380) to Tucatinib (Tukysa): FDA approval) |
m |
||
Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
− | + | *[[Breast cancer, HER2-positive|HER2+ breast cancer]] | |
− | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *4/17/2020: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. | + | *4/17/2020: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive [[breast cancer]], including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. |
==Also known as== | ==Also known as== |
Revision as of 23:46, 21 October 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 4/17/2020: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Also known as
- Code name: ARRY-380, ONT-380
- Generic name: irbinitinib
- Brand name: Tukysa